Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Multiple roles for the receptor tyrosine kinase axl in tumor formation.

Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nör JE, Payan DG, Lorens JB.

Cancer Res. 2005 Oct 15;65(20):9294-303.

2.

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis.

Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ, Pei L.

Oncogene. 2009 Oct 1;28(39):3442-55. doi: 10.1038/onc.2009.212. Epub 2009 Jul 27.

PMID:
19633687
3.

AXL is a potential target for therapeutic intervention in breast cancer progression.

Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G, Ullrich A.

Cancer Res. 2008 Mar 15;68(6):1905-15. doi: 10.1158/0008-5472.CAN-07-2661.

4.

Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read TA, Erber R, Ullrich A.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5799-804. Epub 2006 Apr 3.

5.

HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.

Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, Ramakrishnan S, Shridhar V.

Cancer Res. 2006 Jun 15;66(12):6025-32.

6.

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG, Hitoshi Y.

Cancer Res. 2010 Feb 15;70(4):1544-54. doi: 10.1158/0008-5472.CAN-09-2997. Epub 2010 Feb 9.

7.

Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway.

Scutera S, Fraone T, Musso T, Cappello P, Rossi S, Pierobon D, Orinska Z, Paus R, Bulfone-Paus S, Giovarelli M.

J Immunol. 2009 Sep 1;183(5):3004-13. doi: 10.4049/jimmunol.0804384. Epub 2009 Aug 5.

9.

The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.

Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, Maitra A.

Cancer Biol Ther. 2009 Apr;8(7):618-26. Epub 2009 Apr 22.

10.

Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.

Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S.

Cancer Res. 2006 Apr 15;66(8):4125-32.

11.

Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor.

Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, Bussolino F.

Blood. 2005 Mar 1;105(5):1970-6. Epub 2004 Oct 26.

12.

PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells.

Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, Takahashi H, Wakasugi T, Takeyama H.

Mol Cell Biochem. 2009 Nov;331(1-2):161-71. doi: 10.1007/s11010-009-0154-x. Epub 2009 May 13.

PMID:
19437103
13.

Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases.

Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, Yan L.

Cancer Res. 2005 Apr 15;65(8):3193-9.

14.

A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells.

Png KJ, Halberg N, Yoshida M, Tavazoie SF.

Nature. 2011 Dec 14;481(7380):190-4. doi: 10.1038/nature10661.

PMID:
22170610
15.

Activation of the Axl receptor tyrosine kinase induces mitogenesis and transformation in 32D cells.

McCloskey P, Pierce J, Koski RA, Varnum B, Liu ET.

Cell Growth Differ. 1994 Oct;5(10):1105-17.

16.

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.

Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J.

Oncogene. 2011 Mar 24;30(12):1436-48. doi: 10.1038/onc.2010.509. Epub 2010 Nov 8.

PMID:
21057535
17.

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies.

Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y, Pei L.

Oncogene. 2010 Sep 23;29(38):5254-64. doi: 10.1038/onc.2010.268. Epub 2010 Jul 5.

PMID:
20603615
18.

Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice.

Lamszus K, Jin L, Fuchs A, Shi E, Chowdhury S, Yao Y, Polverini PJ, Laterra J, Goldberg ID, Rosen EM.

Lab Invest. 1997 Mar;76(3):339-53.

PMID:
9121117
19.

AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.

Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W, Luk JM.

Oncogene. 2011 Mar 10;30(10):1229-40. doi: 10.1038/onc.2010.504. Epub 2010 Nov 15.

20.
Items per page

Supplemental Content

Write to the Help Desk